Lilly commits additional $4.5 billion across Indiana manufacturing sites, opens first dedicated genetic medicine facility

Key Points:

• Eli Lilly and Company announced a $4.5 billion investment in its Lebanon, Indiana sites, raising its total capital commitments in the state to over $21 billion since 2020 to support its growing pharmaceutical pipeline and demand.
• The company opened Lilly Lebanon Advanced Therapies, its first dedicated genetic medicine manufacturing facility, designed to produce advanced therapies targeting diseases at the genetic level, alongside plans for additional sites including Lilly Lebanon API and Lilly Medicine Foundry.
• The Lebanon API site will become the largest active pharmaceutical ingredient production site in U.S. history by 2027, manufacturing key medicines such as Zepbound® and Mounjaro® for weight management and type 2 diabetes, as well as Foundayo™, Lilly's first FDA-approved oral weight loss pill, and the investigational drug retatrutide.
• Lilly's investments significantly impact Indiana's economy, accounting for 70% of the state's pharmaceutical GDP and supporting additional jobs, with local economic activity generated up to four times the amount spent by the company.
• The company emphasized its commitment to domestic manufacturing growth, with over $50 billion in U.S. capital expansion since 2020, enabled by supportive policies, and plans to break ground on several new manufacturing sites this year.